Ginkgo Bioworks Holdings Total Liabilities 2020-2022 | DNA

Ginkgo Bioworks Holdings total liabilities from 2020 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Ginkgo Bioworks Holdings Annual Total Liabilities
(Millions of US $)
2021 $504
2020 $205
2019 $0
Ginkgo Bioworks Holdings Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $444
2021-12-31 $504
2021-09-30 $533
2021-06-30 $1,721
2021-03-31 $1,723
2020-12-31
2020-09-30 $0
2019-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.228B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00